Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It promotes pancreatic insulin secretion by inhibiting the DPP-4 enzyme that degrades the GLP-1 and GIP intestinal hormones involved in the physiological regulation of glucose, which are activated by eating (EMA 2016, Baetta 2011, Scheen 2011). Administered orally, once a day.
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic data (EMA 2015, Scheen 2011): low molecular weight, low protein binding, very long half-life, make passage into milk likely in quantity that could be significant, but its high volume of distribution would make this difficult
Infant's blood glucose should be monitored during maternal treatment with alogliptin. (Berlin 2005)
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
Diet, exercise, and breastfeeding improve blood sugar levels.
Common side effects are upper respiratory tract infections, urinary tract infections, gastrointestinal disorders, rash and headaches(EMA, 2015, Scheen 2011) . Low risk of hypoglycemia in monotherapy (EMA, 2015, Scheen 2011). Doses up to 16 times higher than normal for 2 weeks did not produce side effects. (EMA, 2015)
See below the information of these related products: